The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs |
| |
Authors: | Volk Holger A Matiasek Lara A Luján Feliu-Pascual Alejandro Platt Simon R Chandler Kate E |
| |
Institution: | Department of Veterinary Clinical Sciences, Neurology, Royal Veterinary College, Hatfield, UK. hvolk@rvc.ac.uk |
| |
Abstract: | Twenty-two dogs with idiopathic epilepsy which were pharmacoresistant to phenobarbitone and bromide were treated with levetiracetam as an add-on medication. Records of eight dogs were used retrospectively to determine a safe, efficient levetiracetam dosage. Fourteen dogs were entered into a prospective, open label, non-comparative study. After 2 months of levetiracetam oral treatment (10 mg/kg TID), 8/14 dogs responded significantly to the treatment and seizure frequency was reduced by 50%. In dogs that remained refractory, the dosage was increased to 20 mg/kg TID for 2 months. One further dog responded to levetiracetam treatment. Levetiracetam responders had a significant decrease in seizure frequency of 77% (7.9+/-5.2 to 1.8+/-1.7 seizures/month) and a decrease in seizure days per month of 68% (3.8+/-1.7 to 1.2+/-1.1 seizure days/month). However, 6/9 responders experienced an increase in seizure frequency and seizure days after 4-8 months continuing with the levetiracetam treatment at the last effective dosage. Levetiracetam was well tolerated by all dogs and sedation was the only side-effect reported in just one of the 14 dogs. |
| |
Keywords: | Dog Seizure Levetiracetam Antiepileptic drug Refractory |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|